Compare GSK plc (GSK) vs Intuit Inc. (INTU) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Intuit (INTU) trades at $282.43, down 2.52% over the past day, amid a wave of securities fraud investigations related to TurboTax pricing disclosures. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $12.80 versus $12.57 expected, and robust revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Technical indicators are neutral, with RSI at 55.89 and support at $278.

The outlook is mixed: analyst consensus remains bullish with a $422.88 price target and 71% buy ratings, but legal risks and a recent Goldman Sachs downgrade to sell pose near-term headwinds. Long-term growth driven by AI integration in products like Mailchimp offers upside, though investor sentiment is cautious pending legal clarity.